BioTissue® Establishes Medical Advisory Board to Advance Regenerative Biologics in Ocular Care

Industry Leaders to Help Guide BioTissue’s Next Era of Innovation in Ocular Surface Healing

MIAMI, October 2, 2025—BioTissue Holdings Inc., a leader in harnessing the unique power of cryopreserved human birth tissue to support regenerative healing, today announced the formation of its Medical Advisory Board. Comprised of world-renowned Ophthalmologists and Optometrists, the board will provide clinical expertise and strategic counsel to guide BioTissue’s continued innovation in ocular surface disease and other ophthalmic applications of regenerative biologics. 

“Our mission has always been to transform patient outcomes in ophthalmology through regenerative therapies,” said Ted Davis, President and CEO of BioTissue. “This distinguished group of advisors brings unmatched clinical and research experience that will help us accelerate the development and adoption of evidence-based biologic solutions for patients with ocular surface disease and related conditions.”  

Board members include: 

• Eric D. Donnenfeld, MD, is internationally recognized for his leadership in refractive, corneal, and cataract surgery, Dr. Donnenfeld has held presidencies of the American Society of Cataract and Refractive Surgery (ASCRS), the International Intraocular Implant Club (IIIC), and the Ocular Microbiology and Immunology Group (OMIG). His career-long focus on advancing innovation in ophthalmology makes him an invaluable voice in shaping regenerative approaches for corneal and ocular surface disease. 

• Marjan Farid, MD, serves as Clinical Professor and Vice Chair of Ophthalmology at UC Irvine’s Gavin Herbert Eye Institute. She specializes in corneal transplantation, limbal stem cell grafts, artificial corneas, and advanced ocular surface disease management. Her pioneering clinical work and research in ocular regenerative techniques complement BioTissue’s focus on innovation in corneal healing. 

• Paul Karpecki, OD, is the Director of Cornea & External Disease at the Kentucky Eye Institute and is widely regarded as a thought leader in ocular surface disease and dry eye management. A prolific author and contributor to global standards of care, he brings deep expertise in bridging clinical optometry with regenerative biologics to improve patient outcomes. 

• Francis Mah, MD, is the Director of Cornea & External Disease and Co-Director of Refractive Surgery at Scripps Clinic. A leading authority on anterior segment surgery and ocular infectious disease, he has authored more than 100 publications and is the current president of ASCRS. His expertise directly aligns with BioTissue’s work in regenerative therapies for the ocular surface. 

• Selina McGee, OD, FAAO,has dedicated her career to advancing optometric care, with a special focus on ocular disease management. She has been honored as OD of the South and OD of the Year in Oklahoma and brings a clinician’s perspective on integrating innovative biologic therapies into everyday practice for patients with ocular surface conditions. 

For more information about BioTissue’s regenerative ocular therapies, visit biotissue.com/ocular. 

# # # 

About BioTissue Holdings Inc.   

BioTissue^® is an emerging biotechnology company and leader in harnessing the unique power of human birth tissue to support regenerative healing across a wide variety of conditions throughout the body, specializing in ocular surface disease, neurotrophic keratitis, and non-healing corneal defects. BioTissue’s portfolio of Cryopreserved Amniotic Membrane (CAM) products use its proprietary CryoTek^® cryopreservation technology, designed to retain the tissue’s structural and functional integrity. The company continues to break new ground with multiple Investigational New Drug (IND) clinical trials as the company pursues Biologic License Applications (BLAs) for products to treat patients’ unmet clinical needs. BioTissue is committed to empowering healthcare professionals with solutions to deliver optimal patient outcomes by fostering innovation through evidence-based science. Since its inception, clinicians have performed over 1 million human implants with its products and published 420 peer-reviewed publications supporting BioTissue’s platform technology. Learn more at biotissue.com.   

Media Contact:  

Wendy Boyce  

McDougall Communications for BioTissue 

[email protected] or (585) 752-5805